Increased Serum Sclerostin Levels in Patients With Active Acromegaly

Abstract Context Bone mineral density is normal in acromegalic patients and the cause of increased fracture risk that characterizes active acromegaly is unknown. Objective This study compared serum sclerostin levels between patients with active acromegaly and healthy individuals. Design, Setting, an...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2020-03, Vol.105 (3), p.920-924
Main Authors: Pekkolay, Zafer, Kılınç, Faruk, Gozel, Nevzat, Önalan, Ebru, Tuzcu, Alpaslan Kemal
Format: Article
Language:English
Subjects:
Acromegaly
Bone mineral density
Care and treatment
Cellular proteins
Development and progression
Fractures
Gene expression
Genetic aspects
Health aspects
Insulin-like growth factor I
Osteoporosis
SOST protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context Bone mineral density is normal in acromegalic patients and the cause of increased fracture risk that characterizes active acromegaly is unknown. Objective This study compared serum sclerostin levels between patients with active acromegaly and healthy individuals. Design, Setting, and Participants The serum sclerostin levels of patients with active acromegaly were compared with those of healthy volunteers in a cross-sectional study. The mean age of the 30 acromegaly patients (male/female: 14/16) was 47.26 ± 12.52 years (range, 18–64 years) and that of the healthy volunteers (male/female: 17/13) was 44.56 ± 10.74 years (range, 19–62 years). IGF-1 and GH levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an ELISA. The Mann-Whitney U test was used to compare sclerostin levels between the 2 groups. The correlations of sclerostin level with IGF-1 and GH were determined using Spearman’s test. Results The 2 groups did not differ in age or sex (P > 0.05). The median GH and IGF-1 levels in the patient group were 2.49 ng/mL (range, 0.22–70.00 ng/mL) (interquartile range [IQR], 1.3–4.52) and 338.5 ng/mL (range, 147–911 ng/mL) (IQR, 250–426), respectively. The median GH and IGF-1 levels in the control group were 0.95 ng/mL (range, 0.3-2.3) and 144 ng/mL (range, 98–198), respectively. The median sclerostin level was 29.95 ng/mL (range, 7.5–78.1 ng/mL) (IQR, 14.37–37.47) in the acromegaly group and 22.44 ng/mL (range, 8.45–36.44 ng/mL) (IQR, 13.71–27.52) in the control group (P 
ISSN:0021-972X
1945-7197
DOI:10.1210/clinem/dgz254